Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Dec 8;59(12):2136.
doi: 10.3390/medicina59122136.

Remimazolam-Based Anesthesia in Patients with Heart Failure Due to Mitral Regurgitation and Low Left Ventricular Function: A Case Series

Affiliations
Case Reports

Remimazolam-Based Anesthesia in Patients with Heart Failure Due to Mitral Regurgitation and Low Left Ventricular Function: A Case Series

Atsuhiro Kitaura et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Remimazolam is a new ultrashort-acting benzodiazepine anesthetic. Remimazolam appears to be useful in patients with severe valvular disease because of its minimal cardiovascular impact. In this retrospective case series study, we assessed the efficacy and safety of remimazolam for maintaining hemodynamic stability during anesthetic induction and maintenance. Cases: MitraClip was performed on 18 cases with severe mitral regurgitation with low left ventricular function who presented with heart failure, and remimazolam was administered for general anesthesia with induction (12 mg/kg/h) and maintenance (1 mg/kg/h). The impact of remimazolam on the hemodynamics at anesthetic induction and during anesthetic maintenance was investigated retrospectively using electronic medical records. Blood pressure decreased significantly during anesthetic induction with remimazolam (78.5 [72, 81.25] and 66.1 [62.2, 74.2], median [IQR], p = 0.0001), but only mildly, by about 10 mmHg. There was no significant change in the cardiac index (2.0 [1.8, 2.4] vs. 1.9 [1.8, 2.3], p = 0.57642) or pulse rate (73.5 ± 8.85 vs. 74.7 ± 11.7, mean ± SD, p = 0.0876) during anesthetic induction with remimazolam. All patients underwent MitraClip without major hemodynamic concerns, with no or small increases in inotropes. Conclusions: Remimazolam may be used safely in patients with severe mitral regurgitation and low left ventricular function presenting with heart failure.

Keywords: MitraClip; anesthesia; heart failure; mitral regurgitation; remimazolam.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The induction dose of remimazolam in this study. The mean induction dose was also 0.35 mg/kg, which was higher than the 0.1 mg/kg at which all the elderly in the phase I clinical trial fell asleep. There was also a large variation among cases. Whiskers indicate maximum and minimum values.
Figure 2
Figure 2
The changes in cardiovascular parameters before and after induction with remimazolam. MAP decreased significantly after induction, but the change was relatively small. CI and PR were maintained and did not differ significantly. MAP: mean arterial pressure, CI: cardiac index, PR: pulse rate. Whiskers indicate maximum and minimum values.

Similar articles

Cited by

References

    1. Deng H.-B., Li F.-X., Cai Y.-H., Xu S.-Y. Waste anesthetic gas exposure and strategies for solution. J. Anesth. 2018;32:269–282. doi: 10.1007/s00540-018-2448-1. - DOI - PubMed
    1. Cohen I.T., Finkel J.C., Hannallah R.S., Hummer K.A., Patel K.M. Rapid emergence does not explain agitation following sevoflurane anesthesia in infants and children: A comparison with propofol. Paediatr. Anaesth. 2003;13:63–67. doi: 10.1046/j.1460-9592.2003.00948.x. - DOI - PubMed
    1. Hari Y., Satomi S., Murakami C., Narasaki S., Morio A., Kato T., Tsutsumi Y.M., Kakuta N., Tanaka K. Remimazolam decreased the incidence of early postoperative nausea and vomiting compared to desflurane after laparoscopic gynecological surgery. J. Anesth. 2022;36:265–269. doi: 10.1007/s00540-022-03041-y. - DOI - PubMed
    1. Borkett K.M., Riff D.S., Schwartz H.I., Winkle S.P., Panbianco D.J., Lees J.P., Wilhelm-Ogunbiyi K. A phase iia, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth. Analg. 2015;120:771–780. doi: 10.1213/ANE.0000000000000548. - DOI - PubMed
    1. Franken L.G., de Winter B.C.M., Masman A.D., van Dijk M., Baar F.P., Tibboel D., Koch B.C.P., van Gelder T., Mathot R.A.A. Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients. Br. J. Clin. Pharmacol. 2018;84:320–330. doi: 10.1111/bcp.13442. - DOI - PMC - PubMed

Publication types

MeSH terms